AsiaNet  87474

FREIBURG, Germany, January 6, 2021, /PRNewswire=KYODO JBN/--

Eleva, a manufacturer of superior biologics, has secured up to EUR 60 million

in funding from Zukunftsfonds Heilbronn (ZFHN). The funds will help advance one

of its drug candidates, CPV-101, to stages that will facilitate further

investment from venture capitalists and/or pharmaceutical companies. Eleva also

announced the addition of Dr. Ralf Smit to its Executive Board.

Eleva has been utilizing its unique moss-based platform to produce novel drugs.

ZFHN, an investor in local start-ups, is now providing up to EUR 60 million to

help take CPV-101, a potentially game-changing complement regulator, to more

advanced clinical stages. This will enable additional investment from venture

capital firms and/or pharmaceutical companies on the path to approval.

Complement regulators manage inflammatory processes by protecting the body's

own cells and preventing excessive inflammation. Current methods block the

inflammation pathway but promote further infections and pathogen proliferation.

Andreas Schaaf, CSO of Eleva, says:

"ZFHN has been a great supporter and long-term strategic partner. Together we

are convinced that the unprecedented potential of our platform will deliver

tomorrow's therapeutics."

Eleva also announced the addition of Dr. Ralf Smit as CBO (Chief Business

Officer) to its Executive Board. Ralf Smit has over 25 years of experience in

business development and commercialization with pharmaceutical companies

(Roche, BioStrat). Previously an advisor to Eleva, he will now head its

Clinical and Business Development.

About Eleva

Based in Freiburg, Germany, Eleva develops novel biological therapies with its

pharmaceutical partners. The privately-held company leverages its unique

moss-based production platform to produce supreme biologics like antibodies,

replacement enzymes, or fusion toxins. Eleva has successfully developed drug

candidates into clinical phases.

Press contact

eleva GmbH

Fabienne Zeitter

pr@elevabiologics.com

Phone: +49 761 470 990

www.elevabiologics.com

SOURCE: eleva GmbH